| Alexander A Christou, DO | |
|
95 Madison Ave, Suite 101, Morristown, NJ 07960-6092 | |
| (973) 267-1010 | |
| (973) 695-3001 |
| Full Name | Alexander A Christou |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 20 Years |
| Location | 95 Madison Ave, Morristown, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407992068 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 25MB08179500 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Atlantic Home Care & Hospice | Morristown, NJ | Home health agency |
| Morristown Medical Center | Morristown, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Summit Medical Group Pa | 5395642276 | 1253 |
News Archive
GI Dynamics, Inc., a company focused on the development and commercialization of effective, non-surgical approaches for the treatment of type 2 diabetes and obesity, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the EndoBarrier® Gastrointestinal Liner for inclusion on the Australian Register of Therapeutic Goods (ARTG).
Officials are closing some areas on the south shore of Lake Tahoe after some chipmunks tested positive for plague, an infectious disease that affects both humans and other mammals.
Cluster headache has a substantial detrimental effect on quality of life. New invasive procedures, such as hypothalamic deep brain stimulation and bilateral occipital nerve stimulation, may help patients with chronic refractory headache.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.
› Verified 8 days ago
| Entity Name | Summit Medical Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942254347 PECOS PAC ID: 5395642276 Enrollment ID: O20031218000011 |
News Archive
GI Dynamics, Inc., a company focused on the development and commercialization of effective, non-surgical approaches for the treatment of type 2 diabetes and obesity, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the EndoBarrier® Gastrointestinal Liner for inclusion on the Australian Register of Therapeutic Goods (ARTG).
Officials are closing some areas on the south shore of Lake Tahoe after some chipmunks tested positive for plague, an infectious disease that affects both humans and other mammals.
Cluster headache has a substantial detrimental effect on quality of life. New invasive procedures, such as hypothalamic deep brain stimulation and bilateral occipital nerve stimulation, may help patients with chronic refractory headache.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.
› Verified 8 days ago
| Entity Name | Barnabas Health Medical Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841557246 PECOS PAC ID: 9537316955 Enrollment ID: O20120820000951 |
News Archive
GI Dynamics, Inc., a company focused on the development and commercialization of effective, non-surgical approaches for the treatment of type 2 diabetes and obesity, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the EndoBarrier® Gastrointestinal Liner for inclusion on the Australian Register of Therapeutic Goods (ARTG).
Officials are closing some areas on the south shore of Lake Tahoe after some chipmunks tested positive for plague, an infectious disease that affects both humans and other mammals.
Cluster headache has a substantial detrimental effect on quality of life. New invasive procedures, such as hypothalamic deep brain stimulation and bilateral occipital nerve stimulation, may help patients with chronic refractory headache.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alexander A Christou, DO 95 Madison Ave, Suite 101, Morristown, NJ 07960-6092 Ph: (973) 267-1010 | Alexander A Christou, DO 95 Madison Ave, Suite 101, Morristown, NJ 07960-6092 Ph: (973) 267-1010 |
News Archive
GI Dynamics, Inc., a company focused on the development and commercialization of effective, non-surgical approaches for the treatment of type 2 diabetes and obesity, today announced that the Australian Therapeutic Goods Administration (TGA) has approved the EndoBarrier® Gastrointestinal Liner for inclusion on the Australian Register of Therapeutic Goods (ARTG).
Officials are closing some areas on the south shore of Lake Tahoe after some chipmunks tested positive for plague, an infectious disease that affects both humans and other mammals.
Cluster headache has a substantial detrimental effect on quality of life. New invasive procedures, such as hypothalamic deep brain stimulation and bilateral occipital nerve stimulation, may help patients with chronic refractory headache.
Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.
› Verified 8 days ago
Donna Marie Kaminski, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 435 South St Ste 220a, Morristown, NJ 07960 Phone: 973-971-4222 Fax: 973-290-7050 | |
Anthony J Cioce Jr., D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95 Madison Ave, Suite 101, Morristown, NJ 07960 Phone: 973-267-1010 Fax: 973-267-5521 | |
Linda S Hong, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 435 South St Ste 220a, Morristown, NJ 07960 Phone: 973-971-4222 Fax: 973-290-7050 | |
Catherine Guercio-hauer, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 435 South St, Suite 220a, Morristown, NJ 07960 Phone: 973-971-4222 Fax: 973-971-4222 | |
Dr. Jonathan William Torres, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 435 South St, Suite 220, Morristown, NJ 07960 Phone: 973-971-4222 Fax: 862-260-3125 | |
Jamie Tam Moy, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95 Madison Ave Fl 2, Morristown, NJ 07960 Phone: 973-267-1010 Fax: 973-695-3001 | |
Bruce A Aronwald, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 95 Madison Ave, Suite 101, Morristown, NJ 07960 Phone: 973-267-1010 Fax: 973-267-5521 |